Sandoz Group AG Expands European Biosimilar Manufacturing Footprint with New High‑Volume Centre in Slovenia
Sandoz Group AG, a leading global player in the biosimilars market, has announced the inauguration of a new high‑volume drug‑substance manufacturing centre in Lendava, Slovenia. The facility, which incorporates advanced automation and process‑analytical technology, expands the company’s European production network and complements existing continuous‑manufacturing sites in Toulouse and recent investments in Ljubljana. The expansion is presented as a key step toward the firm’s Bio 100 objective of offering more than 100 biosimilars by 2040, and is positioned to enhance supply resilience, support strategic autonomy for biologic medicines and broaden patient access across the region.
Strategic Rationale
The biosimilars market is characterised by stringent regulatory requirements, high capital intensity, and a competitive landscape dominated by a handful of multinational corporations. In this context, manufacturing flexibility and scale are critical to sustaining market share and delivering cost efficiencies. By adding a high‑volume facility in Slovenia, Sandoz gains several strategic advantages:
| Advantage | Description |
|---|---|
| Geographical diversification | A new site in the Central European corridor reduces dependency on any single country and mitigates geopolitical risks. |
| Process optimisation | The plant’s integrated, automated platform allows seamless switching between continuous and batch manufacturing, aligning production with market demand and regulatory pathways. |
| Supply chain resilience | On‑shoring of critical drug‑substance production improves lead times and lowers exposure to global supply disruptions, a lesson underscored by recent semiconductor and pharmaceutical supply chain shocks. |
| Cost competitiveness | Automation and advanced analytics reduce unit manufacturing costs while maintaining rigorous quality controls, thereby strengthening pricing positions against competitors. |
Technological Edge
The Lendava plant is equipped with state‑of‑the‑art process‑analytical technology (PAT), enabling real‑time monitoring of critical quality attributes. This approach aligns with the European Medicines Agency’s (EMA) recommendations for continuous manufacturing and supports rapid product qualification. Key features include:
- Automated upstream and downstream operations: High‑throughput bioreactors, inline purification systems, and robotic material handling reduce manual intervention and human‑error risk.
- Data‑driven decision making: Real‑time analytics feed into a digital twin model that predicts process outcomes and facilitates proactive adjustments.
- Sustainability measures: Energy‑efficient equipment, waste‑reduction protocols, and an emphasis on circular material flows meet the EU’s growing environmental compliance demands.
Workforce and Standards
The facility will employ over 300 specialists, encompassing process engineers, quality assurance personnel, and skilled technicians. All operations will adhere to the highest safety, quality, and environmental standards, consistent with the ISO 9001, ISO 14001, and GMP regulations that govern biologics manufacturing in the EU. The investment in local talent also supports Slovenia’s broader economic objectives of fostering high‑value biotech capabilities.
Alignment with Bio 100 Ambition
Sandoz’s Bio 100 goal—to develop and commercialise more than 100 biosimilars by 2040—requires a robust, globally distributed manufacturing network. The Slovenian centre will serve as a pivotal node that can:
- Accelerate product launch timelines by reducing bottlenecks at existing sites.
- Facilitate technology transfer between research, development, and production phases, thereby shortening the overall innovation cycle.
- Enhance regional patient access by ensuring a reliable supply of critical biologics throughout Central and Eastern Europe.
Market Implications
The biosimilars market is projected to grow at a compound annual growth rate of 9–10 % over the next decade, driven by aging populations, increasing prevalence of chronic diseases, and healthcare cost pressures. Sandoz’s expansion positions it to capture a larger share of this growth trajectory, particularly as pay‑or‑performance reimbursement models gain traction across European health systems.
Competitive analysis reveals that key rivals—such as Roche/Genentech’s biosimilars arm and Amgen’s subsidiary, Amgen Therapeutics—are also investing heavily in advanced manufacturing sites. By establishing a high‑volume, technology‑rich facility in Slovenia, Sandoz maintains parity with these competitors while reinforcing its commitment to sustainability and operational excellence.
Investor and Analyst Engagement
Sandoz has scheduled an investor and analyst site visit in November to provide deeper insight into the new hub’s operations and its role within the broader European biosimilar strategy. This engagement underscores the company’s transparency and willingness to demonstrate its operational capabilities directly to stakeholders—a practice increasingly valued in capital‑market dynamics.
Conclusion
Sandoz Group AG’s new high‑volume manufacturing centre in Lendava represents a strategic investment that aligns with its long‑term Bio 100 objective, enhances supply resilience, and strengthens its competitive positioning in a rapidly evolving biosimilars market. By combining advanced automation, process‑analytical technology, and a commitment to environmental and quality standards, the company demonstrates a disciplined, analytical approach to navigating the sector‑specific dynamics that underpin the global biologics landscape.
